GSK selects Witty as next CEO

Share this article:

GlaxoSmithKline (GSK) has tapped Englishman Andrew Witty to succeed Jean Pierre Garnier as CEO in May.

At age 43, Witty will become the youngest–ever leader of Europe's largest drug maker at a time when the company is seeking to reinvigorate its sales growth.

Witty has worked for the UK-based GSK in the US, Asia and Africa and became president of European operations in 2003.

Witty joined GSK in 1985 in the UK where he held positions as director of pharmacy and distribution and international product manager.

Outside the UK, he was director for south and east Africa and marketing manager for GSK's US unit before moving to Singapore as an Asian SVP.

Garnier, who turns 60 at the end of October, joined SmithKline Beecham in 1990 as president of its North American pharmaceuticals division. He was named CEO in 2000.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...